

## Commentary

Global equities retreated for a second month in October (-0.4%) on a resurgence in COVID-19 cases and risk aversion ahead of the US election. Whilst investors continued to exhibit a slight preference for growth over low multiple - or value - stocks, there was a rotation in the market as Tech underperformed and Financials outperformed. Elsewhere, Consumer Discretionary outperformed, whilst Healthcare and Energy lagged.

US equities fell (-0.6%) as the market began to factor in the potential of a Democratic sweep of the House, Senate and the Presidency against a backdrop of continued gridlock on a new fiscal package. Cyclical outperformed on the potential of more aggressive stimulus under a Blue sweep, while the US technology giants retreated despite posting strong earnings. Europe underperformed as new COVID lockdowns in several major countries weighed on the consumer outlook (-3.7%).

Asia broadly outperformed (+3.2%) led by China (+6.9%) as the relaxation of internal COVID restrictions and the unveiling of the central government's 14th Five Year Plan, led to optimism over momentum in its economic recovery.

Elsewhere, US Treasury yields rose sharply on post-election fiscal hopes. Brent Crude continued to fall on continued demand concerns.

Key contributors to performance included:

- Online Services Asia/Emerging Markets (EM) including Tencent, which benefited from recovery in digital advertising and attention on payments

## Net performance (%)

	Fund	Benchmark	Difference
1 month	2.0	-0.4	2.4
3 month	4.2	2.3	1.9
Year to date	-2.7	-1.0	-1.7
1 year	1.1	2.9	-1.8
Inception p.a.	4.0	9.5	-5.5
Inception	8.1	19.7	-11.6

Past performance is not a reliable indicator of future performance. Returns are calculated net of applicable fees, costs and taxes.

## Top 10 equity longs (%)

Name	Country	Weight
Électricité de France	France	3.2
Tencent	China/HK	3.1
Ping An Insurance	China/HK	3.1
Alibaba	China/HK	2.9
Facebook	United States	2.9
Microsoft	United States	2.8
Siemens	Germany	2.6
Roche	Switzerland	2.5
KB Financial Group	Korea	2.4
Capital One Financial	United States	2.4

## iNAV tickers

	Unit Price	iNAV
Bloomberg	AGX1AU Equity	AGFLIV Index
Thomson Reuters	AGX1AX	AGFLOFV-SOLA
IRESS	AGX1AXW, AGX1.CXA	AGXIV

businesses with the Ant Group IPO, and Alibaba which highlighted ventures in retail and food delivery are moving towards profitability.

- Consumer Cyclical Asia/EM, notably KB Financial and HDFC Bank, as both reported strong results highlighting ongoing normalisation of their domestic economies. In particular, recovery has gathered pace in India and HDFC has taken market share.
- EDF (Infrastructure Developed Markets), which revised full year guidance upwards for nuclear generation and benefited from incremental news around imminent regulatory reform and restructuring.
- Tapestry (Consumer Cyclical DM), which delivered a strong result driven by e-commerce and sales in China. Further, initiatives to focus the product offer, increase prices and reduce discounts have begun to bear fruit.

Key detractors to performance included:

- Healthcare cluster including Merck and Sanofi as pharma has been impacted by the potential for adverse drug pricing policies under a potential Democratic clean sweep in the US elections.
- Oil/natural gas cluster including TechnipFMC which reported a better than expected result but failed to revise full year guidance upwards.
- Siemens (Industrials cluster), following a period of strong performance over the prior six months.


## Fund facts

Characteristics	
Investment manager	Antipodes
Inception date	5 November 2018
Benchmark	MSCI All Country World Net Index in AUD
Management fee	1.10% p.a.
Performance fee	15% of net return in excess of benchmark
Distribution	Annual, 30 June
Unit valuation	Sydney business day

## Asset value

Fund AUM	\$24m
Strategy AUM	\$2,455m
Asset Value (NAV)	5.2288

## Sector exposure<sup>1</sup> (%)




<sup>1</sup> Antipodes classification

**Asset allocation<sup>3</sup>**

	Equities - Long	Other - Long
Weight (% NAV)	91.4	-
Count	61	-
Avg. weight	1.5	-
Top 10 (% NAV)	27.9	-
Top 30 (% NAV)	66.3	-

<sup>3</sup> Call (put) options represented as the current option value (delta adjusted exposure)

**Currency exposure<sup>2,3</sup> (%)**



<sup>2</sup> Where possible, regions, countries and currencies classified on a look through basis.

**Regional exposure<sup>1,2,3</sup> (%)**

Region	Long
United States	32.8
Western Europe	22.2
- Eurozone	16.3
- Rest Western Europe	4.1
- United Kingdom	1.8
Developing Asia	20.9
- China/Hong Kong	18.6
- India	2.3
Developed Asia	13.7
- Korea/Taiwan	8.8
- Japan	5.0
Australia	1.7
<b>Total Equities</b>	<b>91.4</b>
Cash	8.6
<b>Totals</b>	<b>100.0</b>

**Market cap exposure<sup>3</sup> (%)**

Band	Long
Mega (>\$100b)	39.6
Large (>\$25b <\$100b)	29.8
Medium (>\$5b <\$25b)	18.7
Small (<\$5b)	3.3

### Investment Manager

- Global pragmatic value manager, long only and long-short
- Structured to reinforce alignment between investors and the investment team
- We attempt to take advantage of the market's tendency for irrational extrapolation, identify investments that offer a high margin of safety and build portfolios with a capital preservation focus

### Fund features

- **Objective** – to achieve absolute returns in excess of the benchmark over the investment cycle (typically 3-5 years)
- **Global diversification** – Access to 30+ global companies via a single trade
- **Alignment of interests** – proportion of each team member's remuneration is invested into Antipodes funds. Antipodes also has a significant investment alongside unitholders
- **Simple access** – being exchange traded, investors can buy or sell AGX1 like a regular share during the trading day

### Fund Ratings



### Further information

☎ 1300 010 311

✉ [invest@antipodespartners.com](mailto:invest@antipodespartners.com)

### Australia Head Office

Antipodes Partners Limited  
Level 35, 60 Margaret St  
Sydney NSW 2000  
Australia

### UK Office

Antipodes Partners Limited  
6th Floor, Nova North  
11 Bressenden Place  
London SW1E 5BY UK

### Disclaimer

The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned October 2019) referred to in this document is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at <http://www.zenithpartners.com.au/RegulatoryGuidelines>

The Lonsec Ratings (assigned March 2019) presented in this document are published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421445. The Ratings are limited to "General Advice" (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial products. Past performance information is for illustrative purposes only and is not indicative of future performance. They are not a recommendation to purchase, sell or hold Antipodes products, and you should seek independent financial advice before investing in these products. The Ratings are subject to change without notice and Lonsec assumes no obligation to update the relevant documents following publication. Lonsec receives a fee from the Fund Manager for researching the products using comprehensive and objective criteria. For further information regarding Lonsec's Ratings methodology, please refer to our website at: <http://www.beyond.lonsec.com.au/research-solutions/our-ratings>.

Interests in the Antipodes Global Shares (Quoted Managed Fund) ARSN 625 560 269 ('Fund') are issued by Pinnacle Fund Services Limited, ABN 29 082 494 362, AFSL 238371. Antipodes Partners Limited ABN 29 602 042 035 AFSL 481580 ('Antipodes') is the investment manager of the Fund. The Product Disclosure Statement (PDS) for the Fund is available at [www.antipodespartners.com](http://www.antipodespartners.com).

Pinnacle Fund Services Limited is not licensed to provide financial product advice. Any potential investor should consider the current PDS in its entirety and consult their financial adviser before making an investment decision in relation to the Fund. Antipodes and Pinnacle Fund Services Limited believe the information contained in this communication is reliable, however no warranty is given as to its accuracy and persons relying on this information do so at their own risk. Any opinions or forecasts reflect the judgment and assumptions of Antipodes and its representatives on the basis of information at the date of publication and may later change without notice. The information is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. This communication is for general information only. It has been prepared without taking account of any person's objectives, financial situation or needs. Any persons relying on this information should obtain professional advice before doing so. Past performance is not a reliable indicator of future performance.

To the extent permitted by law, Antipodes and Pinnacle Fund Services Limited disclaim all liability to any person relying on the information in respect of any loss or damage (including consequential loss or damage) however caused, which may be suffered or arise directly or indirectly in respect of such information contained in this communication. Options exposure represents the market downside. For put options (typically used to limit potential downside) delta-adjusted exposure is used and for call options (typically used to capture potential upside) exposure is calculated using the current option value.